Pfizer's and Moderna's formulas have been the go-to on pharmacy shelves, but Novavax remains an important option.

20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

NACI added that anyone above 6 months of age who isn't considered high risk "may receive the most recently updated vaccine in ...

As fall approaches and flu season begins, you may have already seen reminders urging you to get your 2024 flu shot. Annual ...

Moderna, once a shining star in the pharmaceutical industry for its rapid development of COVID-19 vaccines, is now facing a ...

Moderna on Thursday said it expects sales of between $2.5 billion and $3.5 billion next year, and forecast that new product launches would drive an average annual growth rate of 25% in revenue between ...

Moderna’s recent stock drop reflects investor concerns over the company’s revised financial outlook and strategic shifts. Despite its pioneering role in mRNA technology and promising future prospects, ...

CVS/Longs Drugs recently announced the availability of the updated COVID-19 and flu vaccinations at the pharmacy and ...

The FDA asked the vaccine manufacturers in June to incorporate the KP.2 strain into their formulas because it was the prevalent form of the virus at the time. Pfizer-BioNTech’s and Moderna’s ...

Moderna is conducting a Phase 1/2 trial of mRNA-1769, a potential mpox vaccine for adults. Early research shows it may ...

Moderna is spending aggressively to broaden the uses of its mRNA technology. Investors are losing patience.